Frontiers of COVID-19

Sasan Adibi, PhD, Senior Member, IEEESchool of ITDeakin UniversityMelbourne, Australia A/Prof Paul GriffinB.Sc. (Hons), MBBS, FRACP, FRCPA, FACTM School of Medicine, University of Queensland, Queensland, AustraliaDepartment of Infectious Diseases, Mater Health, Queensland, AustraliaMelvin Sanicas, MD, MSc, FRSPH, FRSASenior Medical Director, Global Medical AffairsClover BiopharmaceuticalsZurich, Switzerland Maryam Rashidi, MD, PhDSenior Postdoctoral ResearcherImmunology and InflammationWalter & Eliza Hall Institute of Medical Research (WEHI)Melbourne, AustraliaFrancesco Lanfranchi, MDNuclear Medicine UnitDepartment of Health Sciences (DISSAL)University of GenoaGenoa, Italy

• Section I. History, Epidemiologic Background and Pathogenesis of Coronavirus.- Chapter 01: Surfaces as a source for SARS-CoV-2 transmission.- Chapter 02: Humoral immune response in SARS-CoV-2 infection & its therapeutic relevance.- Chapter 03: SARS-CoV-2 Invasion and Pathogenesis of COVID-19: A Perspective of viral receptors, bradykinin and purinergic system.- Chapter 04: Genetics and Biological characteristics of SARS-CoV-2.- Chapter 05: COVID-19 impact on host at pathophysiological and cellular level.- Chapter 06: Identification of the COVID-19 droplet deposition path and its effects on the human respiratory tract before and after the disease: A scoping novel respiratory mask design.- Chapter 07: SARS-CoV-2 variants: Impact of Spike Mutations on Vaccine and Therapeutic strategies.- Chapter 08: Global biologic characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2.- Chapter 09: Emergence of COVID-19 variants and its global impact.- Section II. Clinical Observations.- Chapter 10: Psychological Impacts of the COVID-19 Pandemic.- Chapter 11: Spatial Epidemiology of COVID-19: Disease Risk, Prognosis, and Complications.- Chapter 12: Eye disorders and neuro-ophthalmic manifestations of COVID-19.- Chapter 13: Evaluation and Management of Dysphagia during the COVID-19 Pandemic.- Chapter 14: Gastrointestinal Manifestations Of COVID-19, and Inflammatory Bowel Disease in the COVID-19 Era, Clinical Overview And Updated Guidelines.- Chapter 15: Post COVID-19 conditions-the new challenge to mankind.- Chapter 16: Association of Alpha 1 Antitrypsin deficiency with COVID-19 mortality: basis for clinical trials.- Chapter 17: Social cognition approaches to understanding and changing COVID-19 preventive behaviours.- Chapter 18: Neurological Complications of COVID-19.- Chapter 19: The Impact of Covid-19 on Surgical Disease.- Section III. Interventions and Treatments.- Chapter 20: Pre-Hospital Management of COVID-19: Looking for a Future Perspective.- Chapter 21: Biotechnological strategies in the intervention and treatment of COVID-19.- Chapter 22: Vitamin D: A Potential Prophylactic and Therapeutic Agent against COVID-19.- Section IV. Current Trends and Future Directions.- Chapter 23: Rational repurposing of drugs, clinical trials candidates, and natural products for SARS-Cov-2 therapy.- Chapter 24: In Silico Drug Repositioning for COVID-19: Progress and Challenges.- Chapter 25: Computationally Repurposed Natural Products Targeting SARS-CoV-2 Attachment and Entry Mechanisms.- Chapter 26: Different platforms, immune response modulators and challenges in SARS-CoV-2 vaccination.- Chapter 27: SARS-CoV-2 vaccine against virus: mission accomplished !?.- Chapter 28: COVID-19 vaccines authorized by stringent regulatory authorities and vaccine candidates expecting approval in 2021.- Chapter 29: The Global Evolution of Clinical Practice During a Pandemic.- Chapter 30: Anticipated Long-Term Neurobehavioral Outcomes following COVID-19.- Chapter 31.  The road ahead